[老年非小细胞肺癌治疗方案的现状与前景]
[The status and prospects of treatment protocols for elderly patients with non-small cell lung cancer].
作者信息
Zhou Jianping, Gao Beili
机构信息
Department of Respiratory Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2011 Jul;14(7):598-605. doi: 10.3779/j.issn.1009-3419.2011.07.07.
Abstract
In recent years, the incidence and mortality of advanced lung cancer in elderly patients have been increasing. However, the general acceptance of treatment more than best supportive care in the elderly patients is not optimistic, because the social-economic, family and other factors besides health care were involved in the treatment strategy. In this review, we summarize the current status and prospect of treatment protocols for elderly patients with non-small cell lung cancer.
摘要
近年来，老年晚期肺癌患者的发病率和死亡率一直在上升。然而，老年患者中接受超过最佳支持治疗的普遍接受度并不乐观，因为除了医疗保健外，社会经济、家庭和其他因素也参与了治疗策略。在这篇综述中，我们总结了老年非小细胞肺癌患者治疗方案的现状和前景。
相似文献
1
[The status and prospects of treatment protocols for elderly patients with non-small cell lung cancer].[老年非小细胞肺癌治疗方案的现状与前景]
Zhongguo Fei Ai Za Zhi. 2011 Jul;14(7):598-605. doi: 10.3779/j.issn.1009-3419.2011.07.07.
2
Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.血清白蛋白水平作为体能状态差的老年晚期非小细胞肺癌患者决定化疗或最佳支持治疗的潜在标志物。
BMC Cancer. 2017 Nov 28;17(1):797. doi: 10.1186/s12885-017-3814-3.
3
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.老年晚期非小细胞肺癌的治疗：一个国际专家小组的结果
J Clin Oncol. 2005 May 1;23(13):3125-37. doi: 10.1200/JCO.2005.00.224.
4
Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC).老年晚期肺癌患者的化疗。第二部分：非小细胞肺癌（NSCLC）的治疗。
Onkologie. 2004 Dec;27(6):583-8. doi: 10.1159/000081344.
5
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.治疗老年患者或体能状态为2（PS2）的晚期非小细胞肺癌患者，这些患者无表皮生长因子受体（EGFR）突变和间变性淋巴瘤激酶（ALK）易位——这仍是一项日常挑战。
Eur J Cancer. 2017 Sep;83:266-278. doi: 10.1016/j.ejca.2017.07.002. Epub 2017 Jul 29.
6
Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece.老年非小细胞肺癌患者是否从一线治疗的最新进展中获得了最佳疗效？希腊两个三级癌症中心的一项比较研究。
J Geriatr Oncol. 2015 Mar;6(2):111-8. doi: 10.1016/j.jgo.2014.11.001. Epub 2014 Dec 4.
7
Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.老年晚期非小细胞肺癌的治疗：化疗和靶向药物的作用综述。
J Geriatr Oncol. 2013 Jul;4(3):282-90. doi: 10.1016/j.jgo.2013.04.005. Epub 2013 May 7.
8
Management of the elderly patient with advanced non-small cell lung cancer.老年晚期非小细胞肺癌患者的管理
Int J Clin Pract. 2006 Mar;60(3):340-3. doi: 10.1111/j.1368-5031.2005.00795.x.
9
Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer.老年肺癌的治疗。第一部分：非小细胞肺癌。
Lung Cancer. 2003 Mar;39(3):233-53. doi: 10.1016/s0169-5002(02)00454-3.
10
Chemotherapy of advanced non small cell lung cancer in the elderly: an update.老年晚期非小细胞肺癌的化疗：最新进展
Crit Rev Oncol Hematol. 2000 Sep;35(3):219-25. doi: 10.1016/s1040-8428(99)00064-5.
本文引用的文献
1
Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).III 期 BO17704 研究（AVAiL）中贝伐珠单抗治疗方案在晚期或复发性非鳞状非小细胞肺癌老年患者中的疗效和安全性。
J Thorac Oncol. 2010 Dec;5(12):1970-6. doi: 10.1097/JTO.0b013e3181f49c22.
2
[The retrospective analysis of different therapies on 150 elderly patients with advanced non-small cell lung cancer.].[150例老年晚期非小细胞肺癌不同治疗方法的回顾性分析。]
Zhongguo Fei Ai Za Zhi. 2009 Feb 20;12(2):122-6. doi: 10.3779/j.issn.1009-3419.2009.02.05.
3
Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more.评价 80 岁及以上高龄湿型ⅢB/Ⅳ期非小细胞肺癌患者化疗的疗效和安全性。
Lung Cancer. 2011 Feb;71(2):173-7. doi: 10.1016/j.lungcan.2010.05.014. Epub 2010 Jun 8.
4
[Management and outcome of French elderly patients with lung cancer: an IFCT survey].[法国老年肺癌患者的管理与预后：一项法国胸部肿瘤协作组（IFCT）的调查]
Rev Mal Respir. 2010 May;27(5):421-30. doi: 10.1016/j.rmr.2010.02.013. Epub 2010 Mar 25.
5
6
Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.老年晚期非小细胞肺癌患者的化疗与生存获益。
J Clin Oncol. 2010 May 1;28(13):2191-7. doi: 10.1200/JCO.2009.25.4052. Epub 2010 Mar 29.
7
Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients.老年非小细胞肺癌：与年轻患者相比的临床病理、治疗及预后特征
J Chemother. 2009 Nov;21(5):573-83. doi: 10.1179/joc.2009.21.5.573.
8
Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.老年（>=70 岁）、体能状态差的晚期非小细胞肺癌患者单药口服长春瑞滨的 II 期临床试验。
Ann Oncol. 2010 Jun;21(6):1290-1295. doi: 10.1093/annonc/mdp525. Epub 2009 Nov 13.
9
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.在一个大型老年非小细胞肺癌患者队列中观察到的化疗相关毒性。
J Thorac Oncol. 2010 Jan;5(1):90-8. doi: 10.1097/JTO.0b013e3181c0a128.
10
Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer.一项比较每周紫杉醇联合卡铂与标准紫杉醇联合卡铂治疗老年晚期非小细胞肺癌的随机 II 期临床试验。
Ann Oncol. 2010 Apr;21(4):795-799. doi: 10.1093/annonc/mdp401. Epub 2009 Oct 8.
Zotero 插件